HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1
In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use o...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/194390 |
| Acceso en línea: | https://hdl.handle.net/2445/194390 |
| Access Level: | acceso abierto |
| Palabra clave: | Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| id |
ES_c4d40af3ef0002daa8fb7c19644b81fb |
|---|---|
| oai_identifier_str |
oai:diposit.ub.edu:2445/194390 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1Brasó-Maristany, FaraGriguolo, GaiaChic Ruché, NúriaPascual, TomásParé Brunet, LaiaMaues, JuliaGalván, PatriciaDieci, Maria VittoriaMiglietta, FedericaGiarratano, TommasoMartínez-Sáez, OlgaMarín Aguilera, MercedesSchettini, FrancescoConte, BenedettaAngelats, LauraVidal Losada, Maria JesúsAdamo, BarbaraMuñoz, MontseSanfeliu Torres, Esther González Farré, BlancaVivancos, AnaVillagrasa, PatriciaParker, Joel S.Perou, Charles M.Conte, PierfrancoPrat Aparicio, AleixGuarneri, ValentinaTumors cerebralsMetàstasiCàncer de mamaExpressió gènicaCèl·lules TBrain tumorsMetastasisBreast cancerGene expressionT cellsIn advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC.Oxford University Press2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/194390Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1093/jnci/djac227JNCI: Journal of The National Cancer Institute, 2022https://doi.org/10.1093/jnci/djac227(c) Brasó Maristany, Fara et al., 2022info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1943902026-05-27T06:46:51Z |
| dc.title.none.fl_str_mv |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| spellingShingle |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 Brasó-Maristany, Fara Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| title_short |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_full |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_fullStr |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_full_unstemmed |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| title_sort |
HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 |
| dc.creator.none.fl_str_mv |
Brasó-Maristany, Fara Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
| author |
Brasó-Maristany, Fara |
| author_facet |
Brasó-Maristany, Fara Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
| author_role |
author |
| author2 |
Griguolo, Gaia Chic Ruché, Núria Pascual, Tomás Paré Brunet, Laia Maues, Julia Galván, Patricia Dieci, Maria Vittoria Miglietta, Federica Giarratano, Tommaso Martínez-Sáez, Olga Marín Aguilera, Mercedes Schettini, Francesco Conte, Benedetta Angelats, Laura Vidal Losada, Maria Jesús Adamo, Barbara Muñoz, Montse Sanfeliu Torres, Esther González Farré, Blanca Vivancos, Ana Villagrasa, Patricia Parker, Joel S. Perou, Charles M. Conte, Pierfranco Prat Aparicio, Aleix Guarneri, Valentina |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| topic |
Tumors cerebrals Metàstasi Càncer de mama Expressió gènica Cèl·lules T Brain tumors Metastasis Breast cancer Gene expression T cells |
| description |
In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion |
| format |
article |
| status_str |
acceptedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/194390 |
| url |
https://hdl.handle.net/2445/194390 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Versió postprint del document publicat a: https://doi.org/10.1093/jnci/djac227 JNCI: Journal of The National Cancer Institute, 2022 https://doi.org/10.1093/jnci/djac227 |
| dc.rights.none.fl_str_mv |
(c) Brasó Maristany, Fara et al., 2022 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
(c) Brasó Maristany, Fara et al., 2022 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Oxford University Press |
| publisher.none.fl_str_mv |
Oxford University Press |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Medicina) reponame:Dipòsit Digital de la UB instname:Universidad de Barcelona |
| instname_str |
Universidad de Barcelona |
| reponame_str |
Dipòsit Digital de la UB |
| collection |
Dipòsit Digital de la UB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869418935927963648 |
| score |
15,300724 |